Kazia Therapeutics

KZIA · NASDAQ

$7.81−$0.26 (−3.22%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $8.07

KZIA analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $27.03 (+246.1% upside)

Low: $17.17
Now: $7.81
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

KZIA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Oct 21, 2026	Initiates	Buy	$35.00	31%
Leerink Partners	Oct 20, 2026	Initiates	Outperform	$30.00	47%
BTIG	Sep 10, 2026	Maintains	Buy	$40.00	22%
BTIG	Sep 1, 2026	Maintains	Buy	$34.00 → $40.00	22%
Canaccord Genuity	Aug 13, 2026	Initiates	Buy	$29.00	34%
BTIG	Jul 15, 2026	Maintains	Buy	$34.00	22%
BTIG	Jul 1, 2026	Initiates	Buy	$34.00	22%
Lake Street	Jun 11, 2026	Initiates	Buy	$32.00	—
Laidlaw & Co.	Apr 15, 2026	Initiates	Buy	$25.00	7%
HC Wainwright & Co.	Jan 28, 2026	Maintains	Buy	$18.00	41%

The case for and against

Updated Oct 23, 2026

Bull case

Kazia Therapeutics is attractive because paxalisib combines brain penetration, once-daily oral dosing, and dual PI3K/mTOR inhibition with a novel nuclear-PI3K/EZH2 mechanism that may help overcome metastasis and checkpoint resistance. Early metastatic TNBC data are especially encouraging, with 6/6 evaluable patients achieving clinical benefit and 5/6 objective responses, alongside biomarker improvements such as reduced circulating tumor cell clusters and exhausted T cells, while no serious adverse events or grade 3+ hyperglycemia were reported. The opportunity is amplified by large addressable markets in TNBC, HR+/HER2- breast cancer, and colorectal cancer, plus additional optionality from GBM and pediatric CNS programs, all of which support asymmetric upside from a modest current enterprise value.

Bear case

Kazia Therapeutics is a high-risk oncology developer whose lead asset, paxalisib, still has to prove durable efficacy, an acceptable safety profile, and clear differentiation across TNBC, HR+ breast cancer, CRC, and GBM. The fundamental bearish case is reinforced by weak clinical precedent for PI3K/AKT/mTOR inhibition in TNBC and GBM, where prior programs have shown limited benefit or failed pivotal endpoints, while the FDA has already said existing GBM data are insufficient for an NDA. With no approved products and ongoing execution, regulatory, and commercial uncertainty, higher development spending and potential dilutive financing could pressure value creation before any meaningful revenue traction emerges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.